Back to top

Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup

Technical breakout traders look for a combination that is easy to describe but harder to find in practice: a stock with a confirmed uptrend that is pausing long enough to offer a sensible entry point. ELI LILLY & CO (NYSE:LLY) currently fits both conditions, with a ChartMill Technical Rating of 10 out of 10 and a Setup Quality Rating of 9 out of 10.

ELI LILLY & CO stock chart

Technical strength: a perfect 10

The technical rating is designed to measure the overall health of a stock’s trend, not just its recent price action. It combines long-term and short-term trends, moving average positioning, and relative strength against the broader market. For Eli Lilly & Co., those inputs are about as clean as they get.

  • Long-term and short-term trends are both positive.
  • The stock is trading above its rising SMA20, SMA50, SMA100, and SMA200.
  • Its relative strength score of 92.69 means it has outperformed 92% of all stocks over the past year.
  • Within the Pharmaceuticals industry, it is outperforming 80% of 191 peers.
  • The stock is trading near its 52-week high, with a one-year gain of roughly 73.3%.

This profile aligns with the core idea behind a technical breakout screen. A stock can look attractive for all kinds of reasons, but technicians want to see institutional demand and a persistent uptrend before considering a buy. Eli Lilly has both, and its rising moving averages suggest the trend is broad rather than dependent on a single short-term push. Investors who want to review the charts and indicators behind that score can check the technical analysis report.

Setup quality: a consolidating pattern with defined risk

A strong technical rating alone is not enough for breakout traders. If a stock is already extended, the risk-reward can be poor, and finding a logical stop-loss level becomes difficult. That is why the setup rating is a separate, equally important filter.

Eli Lilly’s setup rating of 9 reflects the recent price behavior: volatility has been reduced while the stock consolidated in a relatively tight area. The report identifies an important support zone between roughly 1135.72 and 1176.78, which should give traders a clear reference point for risk. Resistance sits near 1215.03, with a secondary zone around 1235.56.

The stock also generated a Pocket Pivot signal, a price and volume accumulation pattern that often appears before an institutional move. Taken together, the setup suggests the stock is coiling near resistance with limited overhead supply.

Based on the nearest support and resistance levels, the outlined trade idea uses a buy stop at 1215.04, just above resistance, and a stop-loss exit at 1135.71, below support. That implies a worst-case loss of about 79.33 points, or 6.53%. For traders managing position size carefully, allocating 15.32% of capital to the trade would keep total portfolio risk near 1.00%.

This is where the breakout method matters most. A high technical rating answers the “what to buy” question, while the setup rating answers the “when to buy” question. Eli Lilly is in a strong trend, but it is also showing the kind of controlled consolidation that allows for a relatively tight stop. Even so, breakout setups can fail, especially if unexpected news or earnings arrive before the move, so stops and event awareness remain essential.

Cross-screen confirmation

Eli Lilly also appears on Chartmill’s Strong Momentum Stocks screen, which flags names with strong recent price action and confirmed uptrends (view the Strong Momentum Stocks screen). That independent momentum check reinforces the technical case that the stock’s uptrend is broad enough to support the breakout setup.

Applying the same screen to the market

Eli Lilly is one example of how a technical breakout screen can surface stocks with both trend strength and a defined entry point. Traders who want to apply the same methodology across the broader market can find more candidates in the Technical Breakout Setups screen.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Eli Lilly and Company (LLY)